Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc covers the month of June 2026, specifically reporting on share buyback transactions executed in late May 2026. Haleon is a consumer health company focused on everyday health, with a portfolio spanning oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health. The company operates globally with brands such as Advil, Centrum, Panadol, and Sensodyne.
Key Financial Metrics and Capital Actions
The filing details a significant capital return action rather than operational financial results. On June 1, 2026, Haleon announced the purchase of 10,149,493 ordinary shares for cancellation under a buyback program initiated on March 12, 2026.
| Metric | Value |
|---|---|
| Total Shares Purchased | 10,149,493 |
| Purchase Dates | May 26, 27, 28, and 29, 2026 |
| Price Range (pence) | 336.10 to 346.00 |
| Weighted Average Price (pence) | Approx. 342.00 - 343.14 (varies by venue) |
| Registered Share Capital | 8,859,337,794 shares |
| Treasury Shares Held | 12,076,964 |
| Voting Shares Outstanding | 8,847,260,830 |
The filing does not provide revenue, profit, cash flow, margin, or debt figures for the period.
Material Changes
The primary material change reported is the reduction in the number of shares outstanding due to the cancellation of the 10,149,493 shares purchased. This action reduces the total registered share capital and adjusts the number of voting shares. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It is a regulatory disclosure of share transactions required under the Market Abuse Regulation (EU) No 596/2014 as applied in the UK. The filing explicitly states it does not constitute an offer or solicitation of securities.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying the share volume by the weighted average price to assess cash outflow impact.
- Confirm the updated share count of 8,847,260,830 voting shares for calculating earnings per share (EPS) and ownership percentages.
- Review the full trade breakdown at the provided London Stock Exchange link for granular execution data.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F or earnings releases for revenue and profit metrics.